Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEDO-G dose-finding study of sublingual Phleum pratense immunotherapy
2025-522730-31-00Phase 2Authorised
- Sponsor
- Asacpharma
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of allergovac depot in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Asacpharma. Primary endpoint: Individual response to nasal provocation test. Planned start Oct 2026; status: authorised.
02
Drugs
allergovac depot
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2025-522730-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522730-31-00.